Main Objective: The main objective of this retrospective observational study was to describe the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy Study) scale, for patients with exudative Age-Related Macular Degeneration (ARMD), treated with Lucentis, under real conditions of care, in terms of mean change of the Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).
Study Type
OBSERVATIONAL
Enrollment
250
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
Hopital Saint Joseph
Marseille, France
Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).
Time frame: measured at 24 months (± 4 weeks)
the mean change of the BCVA throughout the 24 months of follow-up (FU),
Time frame: 24 months of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.